Under the Paperwork Reduction Act of 1995, no persons are required to re

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10662459
Filing Date		2003-09-16
First Named Inventor	Steve	en N. Bathiche
Art Unit		2675
Examiner Name	Tamr	my T. Pham
Attorney Docket Numb	er	003797.00546

				Attorney Doc	ket Number	003797.00546			
				U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant Relev		Releva	s,Columns,Lines whe vant Passages or Rele es Appear	
	1	6492979		2002-12-10	Kent, et al.				
	2	5276794		1994-01-04	Lamb, Jr.				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n information pl	lease click the	Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Pat of cited Docu	entee or Applicant iment	Releva	,Columns,Lines ant Passages o s Appear	where r Relevant
	1								
If you wis	h to a	dd additional U.S. Publ	ished Ap	olication citation	n information i	please click the Ad	d button	Add	
				FOREIGN PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code		Name of Patente Applicant of cited Document	e or	Pages,Columns where Relevant Passages or Re Figures Appear	elevant T5
	1								
					l				
If you wish	h to a	dd additional Foreign P		cument citation			button	Remove	

	Application Number		10662459		
INFORMATION DIGGS COURT	Filing Date		2003-09-16		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Stew		ven N. Bathiche		
(Not for submission under 37 CFR 1.99)	Art Unit		2675		
,,	Examiner Name Tam		mmy T. Pham		
	Attorney Docket Numb	er	003797.00546		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

# Examiner Signature Date Considered

\*EXAMINER: Initial if reference considered, whether or not clation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPT/D Patent Documents at year USPT/D\_COV or NEPP 901.04. <sup>2</sup> Enter office that issued the document, by the bro-bitter code (NIPO Standard ST.3). <sup>2</sup> Sort planetee patent concurrents, the action of the year of the Emperor must procede the sent number of the section counters. It was closed not be of the Emperor must procede the sent number of the section counters. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>5</sup> Applicant is to place a check mark their of English languages the relatation is attached.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10662459
Filing Date		2003-09-16
First Named Inventor	Steve	en N. Bathiche
Art Unit		2675
Examiner Name	Tamr	ny T. Pham
Attorney Docket Numb	er	003797.00546

#### CERTIFICATION STATEMENT

Please see	37	CER .	1 97	and	1 02	to	make the	annro	nniata	colo	ction/	(e)	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sec 37 CFR 197(eV1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, not not information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/9/(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/H. Wayne Porter/	Date (YYYY-MM-DD)	2006-07-24
Name/Drint	Li Wayne Borter	Desistration Number	42.004

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. D. 6bb 1450, Alexandria, V.S. 2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.